Here, the results are equivocal, with some studies finding no effect of the ACE I/D polymorphism on muscle phenotype (McCauley et al., 2010; Garatachea et al., 2012), and others reporting that it modified the response to resistance training (Pereira et al., 2013), both on its own and in combination with ACTN3. Like ACTN3, ACE may also impact longevity through a variety of different pathways, including metabolic disease risk (Kajantie et al., 2004), blood pressure control (Yoshida et al., 2000; Santana et al., 2011), and Alzheimer’s disease risk (Narain et al., 2000). Here, ACE is linked to Other metabolic disease.